Chinese Journal of Dermatology ›› 2023, Vol. 56 ›› Issue (6): 489-495.doi: 10.35541/cjd.20230004
• Guidelines and Consensus • Previous Articles Next Articles
Chinese Society of Dermatology, China Dermatologist Association
Received:2023-01-03
Revised:2023-03-10
Online:2023-06-15
Published:2023-06-05
Contact:
Xiao Ting; Zhao Zuotao; Gao Xinghua
E-mail:cmuxt@126.com; zhaozuotaotao@163.com; gaobarry@hotmail.com
Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023）[J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.doi:10.35541/cjd.20230004
| ［1］ | Kolkhir P, Giménez⁃Arnau AM, Kulthanan K, et al. Urticaria［J］. Nat Rev Dis Primers, 2022,8（1）:61. doi: 10.1038/s41572⁃022⁃00389⁃z. |
| ［2］ | Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342. |
| ［3］ | Maurer M, Weller K, Bindslev⁃Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report［J］. Allergy, 2011,66（3）:317⁃330. doi: 10.1111/j.1398⁃9995.2010.02496.x. |
| ［4］ | Kim YS, Park SH, Han K, et al. Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population［J］. Br J Dermatol, 2018,178（4）:976⁃977. doi: 10. 1111/bjd.16105. |
| ［5］ | Xiao Y, Huang X, Jing D, et al. The prevalence of atopic dermatitis and chronic spontaneous urticaria are associated with parental socioeconomic status in adolescents in China［J］. Acta Derm Venereol, 2019,99（3）:321⁃326. doi: 10.2340/00015555⁃3104. |
| ［6］ | 于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091. |
| ［7］ | Dong W, An J, Geng P, et al. Years lost due to disability from skin diseases in China 1990⁃2017: findings from the Global Burden of Disease Study 2017［J］. Br J Dermatol, 2020,182（1）:248⁃250. doi: 10.1111/bjd.18329. |
| ［8］ | Huang Y, Xiao Y, Zhang X, et al. A meta⁃analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety［J］. Front Med （Lausanne）, 2020,7:39. doi: 10.3389/fmed.2020.00039. |
| ［9］ | Kulthanan K, Chusakul S, Recto MT, et al. Economic burden of the inadequate management of allergic rhinitis and urticaria in Asian countries based on the GA2LEN model［J］. Allergy Asthma Immunol Res, 2018,10（4）:370⁃378. doi: 10.4168/aair.2018.10. 4.370. |
| ［10］ | Maurer M, Raap U, Staubach P, et al. Antihistamine⁃resistant chronic spontaneous urticaria: 1⁃year data from the AWARE study［J］. Clin Exp Allergy, 2019,49（5）:655⁃662. doi: 10.1111/cea.13309. |
| ［11］ | De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies［J］. Acta Derm Venereol, 2021,101（2）:adv00402. doi: 10.2340/00015555⁃3751. |
| ［12］ | Gisondi P, Talamonti M, Chiricozzi A, et al. Treat⁃to⁃target approach for the management of patients with moderate⁃to⁃severe plaque psoriasis: consensus recommendations［J］. Dermatol Ther （Heidelb）, 2021,11（1）:235⁃252. doi: 10.1007/s13555⁃020⁃00475⁃8. |
| ［13］ | Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force［J］. Ann Rheum Dis, 2016,75（1）:3⁃15. doi: 10.1136/annrheumdis⁃2015⁃207524. |
| ［14］ | Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat⁃to⁃target in systemic lupus erythematosus: advancing towards its implementation［J］. Nat Rev Rheumatol, 2022,18（3）:146⁃157. doi: 10.1038/s41584⁃021⁃00739⁃3. |
| ［15］ | 赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议［J］. 中国皮肤性病学杂志, 2022,36（8）:855⁃864. doi: 10.13735/j.cjdv.1001⁃7089.202205115. |
| ［16］ | Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050. |
| ［17］ | Yanase Y, Takahagi S, Ozawa K, et al. The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria［J］. Cells, 2021,10（7）:1759. doi: 10.3390/cells10071759. |
| ［18］ | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
| ［19］ | Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all.15090. |
| ［20］ | Antia C, Baquerizo K, Korman A, et al. Urticaria: a comprehensive review: epidemiology, diagnosis, and work⁃up［J］. J Am Acad Dermatol, 2018,79（4）:599⁃614. doi: 10.1016/j.jaad.2018.01.020. |
| ［21］ | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609. |
| ［22］ | 张敏, 崔振泽, 李悦, 等. 嗜碱性粒细胞活化试验在过敏性疾病应用中的研究进展［J］. 中国免疫学杂志, 2021,37（22）:2803⁃2809. doi: 10.3969/j.issn.1000⁃484X.2021.22.021. |
| ［23］ | Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372, 1372.e1⁃6. doi: 10. 1016/j.jaci.2013.12.1076. |
| ［24］ | 于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190. |
| ［25］ | Zhao Z, Zhang C, Jiang Y, et al. Chinese version of the chronic urticaria quality of life questionnaire: cultural adaptation, factor analysis, assessment of reliability and validity［J］. Arch Dermatol Res, 2022,314（9）:847⁃855. doi: 10.1007/s00403⁃021⁃02300⁃4. |
| ［26］ | Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score［J］. Allergy, 2013,68（9）:1185⁃1192. doi: 10.1111/all.12209. |
| ［27］ | Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test （AECT）⁃a patient⁃reported outcome instrument for assessing angioedema control［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2050⁃2057.e4. doi: 10.1016/j.jaip. 2020.02.038. |
| ［28］ | Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire［J］. Allergy, 2012,67（10）:1289⁃1298. doi: 10.1111/all.12007. |
| ［29］ | Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x. |
| ［30］ | 于淼, 陈玉迪, 刘擘, 等. 慢性自发性荨麻疹的临床评估体系［J］. 中华皮肤科杂志, 2021,54（12）:1117⁃1121. doi: 10.35541/cjd.20210379. |
| ［31］ | Simons FE, Simons KJ. Histamine and H1⁃antihistamines: celebrating a century of progress［J］. J Allergy Clin Immunol, 2011,128（6）:1139⁃1150.e4. doi: 10.1016/j.jaci.2011.09.005. |
| ［32］ | Yuan W, Hu S, Li M, et al. Efficacy and safety of omalizumab in Chinese patients with anti⁃histamine refractory chronic spontaneous urticaria［J］. Dermatol Ther, 2022,35（4）:e15303. doi: 10.1111/dth.15303. |
| ［33］ | Zhao Z, Cai T, Chen H, et al. Expert consensus on the use of omalizumab in chronic urticaria in China［J］. World Allergy Organ J, 2021,14（11）:100610. doi: 10.1016/j.waojou.2021.100610. |
| ［34］ | Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both［J］. World Allergy Organ J, 2021,14（1）:100501. doi: 10.1016/j.waojou.2020.100501. |
| ［35］ | Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China［J］. Ann Allergy Asthma Immunol, 2020,125（2）:217⁃219. doi: 10.1016/j.anai.2020.04.026. |
| ［36］ | Khan DA, Kocatürk E, Bauer A, et al. What′s new in the treatment of urticaria and angioedema［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2170⁃2184. doi: 10.1016/j.jaip.2021.03.012. |
| ［37］ | He L, Yi W, Huang X, et al. Chronic urticaria: advances in understanding of the disease and clinical management［J］. Clin Rev Allergy Immunol, 2021,61（3）:424⁃448. doi: 10.1007/s12016⁃ 021⁃08886⁃x. |
| ［38］ | Türk M, Yılmaz İ, Şahiner ÜM, et al. Experience⁃based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: where is the guidance?［J］. Allergy, 2022,77（5）:1626⁃1630. doi: 10.1111/all.15227. |
| ［39］ | Zhang L, Wu J, Qi Y, et al. Long⁃term combinations and updosing of second⁃generation H1⁃antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: a multicenter real⁃life pilot study［J］. J Allergy Clin Immunol Pract, 2020,8（5）:1733⁃1736.e11. doi: 10.1016/j.jaip.2019.12.006. |
| ［40］ | Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. doi: 10.1016/j.jaip.2017.07.017. |
| ［41］ | Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. doi: 10.1111/all.14686. |
| ［42］ | Hansen C, Desrosiers TA, Wisniewski K, et al. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997⁃2011［J］. Birth Defects Res, 2020,112（16）:1234⁃1252. doi: 10. 1002/bdr2.1749. |
| ［43］ | Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry （EXPECT）: the safety of omalizumab use during pregnancy［J］. J Allergy Clin Immunol, 2015, 135（2）:407⁃412. doi: 10.1016/j.jaci.2014.08.025. |
| ［44］ | Liao SL, Yu M, Zhao ZT, et al. Case report: omalizumab for chronic spontaneous urticaria in pregnancy［J］. Front Immunol, 2021,12:652973. doi: 10.3389/fimmu.2021.652973. |
| ［45］ | Kocatürk E, Podder I, Zenclussen AC, et al. Urticaria in pregnancy and lactation［J］. Front Allergy, 2022,3:892673. doi: 10.3389/falgy.2022.892673. |
| ［46］ | Kulthanan K, Rujitharanawong C, Munprom K, et al. Prevalence, clinical manifestations, treatment, and clinical course of chronic urticaria in elderly: a systematic review［J］. J Asthma Allergy, 2022,15:1455⁃1490. doi: 10.2147/JAA.S379912. |
| ［47］ | Longhurst HJ, Gonçalo M, Godse K, et al. Managing chronic urticaria and recurrent angioedema differently with advancing age［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2186⁃2194. doi: 10.1016/j.jaip.2021.03.034. |
| ［48］ | 陈玉迪, 胡艳, 隋海晶, 等. 抗IgE单克隆抗体在变态反应性疾病治疗中的应用［J］. 中华临床免疫和变态反应杂志, 2018,12（3）:302⁃307. doi: 10.3969/j.issn.1673⁃8705.2018.03.008. |
| [1] | Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539. |
| [2] | Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488. |
| [3] | Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update [J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562. |
| [4] | Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566. |
| [5] | Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558. |
| [6] | Zhang Liming, Xiao Ting. Update of the autoimmune pathogenesis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 567-570. |
| [7] | Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524. |
| [8] | Chen Qiquan, Kong Minmin, Yang Xianjie, Wang Huan, Li Jian, Zhang Mingwang, Song Zhiqiang. Clinical analysis of allergen reactivity and atopic disease history in 168 patients with chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 496-503. |
| [9] | Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517. |
| [10] | Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530. |
| [11] | Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511. |
| [12] | Writing Committee Expert Group on “Treatment of mycosis fungoides: a Chinese expert consensus （）”. Treatment of mycosis fungoides: a Chinese expert consensus （2023） [J]. Chinese Journal of Dermatology, 2023, 56(5): 402-409. |
| [13] | Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Committee on Dermatology, Chinese Association of Geriatric Research, Committee on Dermatological Drug Research, The Chinese Association of Traditional Chinese Medicine. Expert consensus on integrated traditional Chinese and Western medicine for eczema and dermatitis [J]. Chinese Journal of Dermatology, 2023, 56(4): 287-293. |
| [14] | Yang Xiaojing, Chen Leigang, Wang Shining, Wu Yuanhui, Zhu Youjin, An Guozhi, Zhou Xiangzhao, Meng Zhaoying. Correlation of serum interleukin-9 and platelet-activating factor levels with total IgE levels, disease severity and disease course in patients with chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(4): 337-341. |
| [15] | Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203. |
|
